$CLLS Cashflow Statement | Understand Stock

$CLLS

$1.05 +$0.08 (8.64%) Close

$CLLS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Consolidated Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net income (loss)
Net loss for the period from discontinued operations
Net (loss) income for the period from continuing operations
Adjustment to reconcile net income (loss) to cash provided by (used in) operating activities
Intercompany transactions between continuing and discontinued operations
Amortization and depreciation
Net loss (income) on disposals
Net financial loss (gain)
Income tax
Expenses related to share-based payments
Provisions
Other non-cash items
Gain upon the forgiveness of the Payroll Protection Program loan
Realized foreign exchange gain (loss)
Interest (paid) / received

Operating cash flows before change in working capital
Decrease (increase) in inventories
Decrease (increase) in trade receivables and other current assets
Decrease (increase) in subsidies and tax receivables
(Decrease) increase in trade payables and other current liabilities
(Decrease) increase in deferred revenues and contract liabilities
Change in working capital
Interest received
Income tax received (paid)
Net cash flows provided by (used in) operating activities of continuing operations
Net cash flows provided by (used in) operating activities of discontinued operations
Net cash flows provided by (used in) operating activities
Cash flows from investment activities
Acquisition of intangible assets
Calyxt's cash and cash equivalents disposed of
Acquisition of property, plant and equipment
Net change in non-current financial assets
Sales of non-current financial assets
Sale of current financial assets
Acquisition of non-current financial assets
Acquisition of current financial assets
Net cash flows provided by (used in) investing activities of continuing operations
Net cash flows provided by (used in) investing activities of discontinued operations
Cash flows provided by (used in) investment activities
Cash flows from financing activities
Proceeds from the exercise of Cellectis stock options
Proceeds from the exercise of Calyxt stock options
Increase in share capital of Cellectis after deduction of transaction costs
Proceeds from issue of share capital and other equity instruments after deduction of transaction costs
Increase in borrowings
Decrease in borrowings
Interest paid on financial debt
Payments on lease debts
Net cash flows provided by (used in) financing activities of continuing operations
Net cash flows provided by (used in) financing activities of discontinued operations
Net cash flows provided by (used in) financing activities

(Decrease) increase in cash and cash equivalents
Cash and cash equivalents at the beginning of the year
Calyxt Inc
Total cash and cash equivalents at the beginning of the year
Effect of exchange rate changes on cash
Cash from discontinued operations
Cash from continuing operations
Cash and cash equivalents at the end of the period
Calyxt Inc
Total cash and cash equivalents at the end of the period

Comments